Literature DB >> 17553719

Inducible nitric oxide synthase and histopathological correlation in chronic viral hepatitis.

Esin Atik1, Yusuf Onlen, Lutfu Savas, Figen Doran.   

Abstract

BACKGROUND: Chronic liver disorders represent a serious health problem. Nitric oxide (NO) synthesized by inducible nitric oxide synthase (iNOS) can function as an antimicrobial agent able to kill or reduce replication of microorganisms, and plays an important role in immune regulation. This study was undertaken to evaluate the expression of iNOS in chronic viral hepatitis and its relation to histopathology.
METHODS: This study included 56 patients with chronic viral hepatitis (38 hepatitis B, 18 hepatitis C). There were 35 men and 21 women with a mean age of 38.6+/-21.731 years. A modified form of the histology activity index (HAI) designed by Ishak and colleagues was used to assess grading and staging of chronic viral hepatitis. The needle biopsy specimens were fixed in 10% formalin and routinely processed. Routine hematoxylin-eosin, periodic acid-Schiff, and reticulin staining, and iNOS immunoperoxidase technique were performed on paraffin-embedded tissues.
RESULTS: We demonstrated that all liver samples had a marked iNOS expression, with a diffuse distribution pattern. iNOS consistently labeled mononuclear cells infiltrating portal tracts in all samples. Statistical evaluation of data showed that the iNOS expression correlated with the HAI and fibrosis. Furthermore a correlation between iNOS and severity of disease was detected (r=0.772, p=0.000).
CONCLUSIONS: Further investigations are required to determine whether iNOS-related treatment protocols could be useful in reducing disease severity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553719     DOI: 10.1016/j.ijid.2007.03.010

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  7 in total

1.  Effects of interleukin-10 gene deficiency on hepatic biochemical metabolism in mice.

Authors:  Jing Du; Jian Zhang; Dexue Zou; Liang Ye; G George Chen; Chao Yang
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 3.984

2.  Amifostine enhances the antioxidant and hepatoprotective effects of UW and HTK preservation solutions.

Authors:  Sami Akbulut; Sinasi Sevmis; Hamdi Karakayali; Nilüfer Bayraktar; Muge Unlukaplan; Ergun Oksuz; Atilla Dagdeviren
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

3.  SKLB023 hinders renal interstitial fibrosis in obstructive nephropathy by interfering TGF-β1/Smad3 signaling.

Authors:  Yanhuan Feng; Jun Xu; Fan Guo; Rongshuang Huang; Min Shi; Lingzhi Li; Liang Ma; Ping Fu
Journal:  RSC Adv       Date:  2018-02-06       Impact factor: 4.036

Review 4.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

5.  Established Principles and Emerging Concepts on the Interplay between Mitochondrial Physiology and S-(De)nitrosylation: Implications in Cancer and Neurodegeneration.

Authors:  Giuseppina Di Giacomo; Salvatore Rizza; Costanza Montagna; Giuseppe Filomeni
Journal:  Int J Cell Biol       Date:  2012-08-13

6.  "Non alcoholic fatty liver disease and eNOS dysfunction in humans".

Authors:  Marcello Persico; Mario Masarone; Antonio Damato; Mariateresa Ambrosio; Alessandro Federico; Valerio Rosato; Tommaso Bucci; Albino Carrizzo; Carmine Vecchione
Journal:  BMC Gastroenterol       Date:  2017-03-07       Impact factor: 3.067

7.  SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway.

Authors:  Jinhang Zhang; Yanping Li; Qinhui Liu; Rui Li; Shiyun Pu; Lina Yang; Yanhuan Feng; Liang Ma
Journal:  RSC Adv       Date:  2018-09-03       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.